Besipirdine
Alternative Names: HP 749; P 867493Latest Information Update: 17 Mar 2009
At a glance
- Originator sanofi-aventis
- Developer UroGene
- Class Indoles; Pyridines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Overactive bladder
- Discontinued Alzheimer's disease
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 09 Jun 2004 Phase-II clinical trials in Overactive bladder in France (PO)
- 07 Jan 2004 Besipiridine has been licensed to UroGene worldwide for the treatment of overactive bladder